WallStreetZenWallStreetZen

NASDAQ: ILMN
Illumina Inc Stock

$108.66-0.56 (-0.51%)
Updated Jun 14, 2024
ILMN Price
$108.66
Fair Value Price
$57.28
Market Cap
$17.31B
52 Week Low
$89.00
52 Week High
$203.19
P/E
-13.33x
P/B
3.02x
P/S
4.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.49B
Earnings
-$1.29B
Gross Margin
61.4%
Operating Margin
-23.88%
Profit Margin
-28.7%
Debt to Equity
0.75
Operating Cash Flow
$545M
Beta
1.09
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ILMN Overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ILMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ILMN ($108.66) is overvalued by 89.71% relative to our estimate of its Fair Value price of $57.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ILMN ($108.66) is not significantly undervalued (89.71%) relative to our estimate of its Fair Value price of $57.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ILMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ILMN due diligence checks available for Premium users.

Be the first to know about important ILMN news, forecast changes, insider trades & much more!

ILMN News

Valuation

ILMN fair value

Fair Value of ILMN stock based on Discounted Cash Flow (DCF)
Price
$108.66
Fair Value
$57.28
Overvalued by
89.71%
ILMN ($108.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ILMN ($108.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ILMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ILMN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-13.33x
Industry
38.76x
Market
30.51x

ILMN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.02x
Industry
4.25x
ILMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ILMN's financial health

Profit margin

Revenue
$1.1B
Net Income
-$126.0M
Profit Margin
-11.7%
ILMN's Earnings (EBIT) of -$1.07B... subscribe to Premium to read more.
Interest Coverage Financials
ILMN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.0B
Liabilities
$4.3B
Debt to equity
0.75
ILMN's short-term assets ($2.58B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ILMN's long-term liabilities ($2.83B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ILMN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ILMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$77.0M
Investing
-$48.0M
Financing
$35.0M
ILMN's operating cash flow ($545.00M)... subscribe to Premium to read more.
Debt Coverage Financials

ILMN vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
ILMN$17.31B-0.51%-13.33x3.02x
WAT$17.50B-0.19%28.89x13.92x
LH$16.85B+1.73%39.19x2.12x
DGX$15.31B-0.49%18.31x2.38x
NTRA$13.53B-0.53%-35.32x17.04x

Illumina Stock FAQ

What is Illumina's quote symbol?

(NASDAQ: ILMN) Illumina trades on the NASDAQ under the ticker symbol ILMN. Illumina stock quotes can also be displayed as NASDAQ: ILMN.

If you're new to stock investing, here's how to buy Illumina stock.

What is the 52 week high and low for Illumina (NASDAQ: ILMN)?

(NASDAQ: ILMN) Illumina's 52-week high was $203.19, and its 52-week low was $89.00. It is currently -46.52% from its 52-week high and 22.09% from its 52-week low.

How much is Illumina stock worth today?

(NASDAQ: ILMN) Illumina currently has 159,300,000 outstanding shares. With Illumina stock trading at $108.66 per share, the total value of Illumina stock (market capitalization) is $17.31B.

Illumina stock was originally listed at a price of $19.59 in Jul 28, 2000. If you had invested in Illumina stock at $19.59, your return over the last 23 years would have been 454.81%, for an annualized return of 7.73% (not including any dividends or dividend reinvestments).

How much is Illumina's stock price per share?

(NASDAQ: ILMN) Illumina stock price per share is $108.66 today (as of Jun 14, 2024).

What is Illumina's Market Cap?

(NASDAQ: ILMN) Illumina's market cap is $17.31B, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Illumina's market cap is calculated by multiplying ILMN's current stock price of $108.66 by ILMN's total outstanding shares of 159,300,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.